2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1619

The Impact of Disease Characteristics on Habitual Physical Activity and Sedentary Behavior Among Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 1620

Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1621

Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By the Automated Neuropsychological Assessment Metrics
Abstract Number: 1622

Associations Among Classification Criteria Items within Systemic Lupus Erythematosus
Abstract Number: 1623

Prevalence of Cognitive Impairment in Systemic Lupus Erythematosus Assessed By a Comprehensive Neuropsychological Battery
Abstract Number: 1624

SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Abstract Number: 1625

Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Abstract Number: 1626

Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Abstract Number: 1627

Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis
Abstract Number: 1628

Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population
Abstract Number: 1629

Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Abstract Number: 1630

Achievement of Lupus Low Disease Activity State (LLDAS) in the Early Phase of Systemic Lupus Erythematosus Prevent Damage Accrual
Abstract Number: 1631

Hospital Readmissions for SLE in the United States: A National Database Study
Abstract Number: 1632

SLE Characteristics Associated with Modified Framingham Risk Score in Patients without Clinical Cardiovascular Disease
Abstract Number: 1633

Use of Emergency Department (ED) and Resulting Hospitalization By Patients with Systemic Lupus Erythematosus (SLE) in a Predominantly Afro-Caribbean Inner-City Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].